中年期前COPD肺功能轨迹的生物标志物:1至6个十年段的前瞻性研究
基于塔斯马尼亚纵向健康研究(n=2442)的7至53岁肺功能数据,建模终生FEV1/FVC轨迹,并在53岁时检测CC16、sRAGE、CRP、ECP、SPD、纤维蛋白原及多种细胞因子。结果显示CC16、sRAGE、SPD、IL-17A、IL-5和IL-10在三种前COPD轨迹与正常轨迹间存在显著差异,并可区分快速下降与相对稳定轨迹。CART分析识别出可区分不同前COPD轨迹的生物标志物组合。
要点
- CC16、sRAGE、SPD、IL-17A、IL-5和IL-10在三种前COPD轨迹与正常轨迹间存在显著差异。
- 上述标志物可在前COPD轨迹内部区分两种快速下降轨迹与相对稳定轨迹。
- CART分析识别出可区分不同前COPD轨迹的生物标志物组合,联合临床病史或有助于识别高危者。
核心结论
- 已确立的COPD生物标志物在前COPD阶段即已活跃,并可区分前COPD肺功能轨迹。
- 生物标志物尤其结合临床病史,可能有助于识别高危人群并优化前COPD与COPD的管理。
研究设计与样本
- 塔斯马尼亚纵向健康研究,利用7至53岁肺功能数据建模终生FEV1/FVC轨迹(n=2442)。
- 53岁时检测血清CC16、sRAGE、CRP、ECP、SPD、纤维蛋白原及多种细胞因子,并与FEV1/FVC轨迹关联。
- 采用分类与回归树(CART)分析生物标志物组合与前COPD轨迹分布的关系。
主要发现
- 六种FEV1/FVC轨迹中,三种COPD风险升高的前COPD轨迹为「早期低值-快速下降」「早期正常-快速下降」和「早期低值-正常下降」。
- CC16、sRAGE、SPD、IL-17A、IL-5和IL-10在三种前COPD轨迹与正常轨迹间存在显著差异。
- 在前COPD轨迹内部,这些生物标志物可区分两种快速下降轨迹与相对稳定轨迹。
- CART分析识别出可区分不同前COPD轨迹的不同生物标志物组合。
临床怎么用
- 对中年人可考虑检测CC16、sRAGE、SPD、IL-17A、IL-5和IL-10等标志物,结合临床病史评估前COPD轨迹风险。
- 生物标志物组合或有助于区分快速下降与相对稳定的前COPD轨迹,辅助早期识别与分层管理。
局限性
- 儿童期起重复肺量计测量在实际中很少可得,本研究依托独特纵向队列数据。
- 生物标志物仅在53岁时单次检测,与轨迹的时序关系有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Identifying impaired lifetime lung function trajectories and their underlying biological pathways is key to characterising the preclinical phase of COPD (Pre-COPD) and its progression. However, this is challenging in practice as repeated spirometry measurements from childhood are rarely available. We investigated potential blood biomarkers associated with pre-COPD trajectories. METHODS: The Tasmanian Longitudinal Health Study has unique lung function data from 7 to 53 years, from which lifetime FEV1/FVC trajectories were modelled (n = 2442). Serum levels of CC16, sRAGE, CRP, ECP, SPD, fibrinogen and a range of cytokines were quantified at 53 years of age. These were related to respective FEV1/FVC trajectories. Classification And Regression Tree (CART) analysis was used to investigate biomarker combinations in relation to the distribution of pre-COPD FEV1/FVC trajectories. RESULTS: Among six FEV1/FVC trajectories, three trajectories at increased risk of COPD (pre-COPD trajectories) were 'Early Low-Rapid Decline', 'Early Normal-Rapid Decline' and 'Early Low-Normal Decline'. CC16, sRAGE, SPD, IL-17A, IL-5 and IL-10 differed significantly between these three pre-COPD and the normal trajectory. Notably, within the pre-COPD trajectories, these biomarkers also differentiated two rapid decline trajectories from the relatively stable one. CART analysis identified different combinations of biomarkers that distinguish different pre-COPD trajectories. CONCLUSION: This is the first study to show that established COPD biomarkers are already active during the pre-COPD phase and could distinguish pre-COPD lung function trajectories. Biomarkers, particularly together with clinical history, may have the potential to identify those at risk and optimise management of both Pre-COPD and COPD.
引用
- Bui DS, Vicendese D, Pham J, et al. Biomarkers of Pre-COPD Lung Function Trajectories in Middle Age: A Prospective Study From 1st to 6th Decade. Respirology. 2026. PMID: 42442716. doi:10.1002/resp.70279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。